1. Home
  2. CRCT vs ABUS Comparison

CRCT vs ABUS Comparison

Compare CRCT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cricut Inc.

CRCT

Cricut Inc.

HOLD

Current Price

$4.24

Market Cap

857.6M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

875.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRCT
ABUS
Founded
1969
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.6M
875.7M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
CRCT
ABUS
Price
$4.24
$4.35
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
2
1
Target Price
$3.50
$5.00
AVG Volume (30 Days)
484.4K
1.8M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
22.25%
N/A
EPS Growth
20.69
55.26
EPS
0.35
N/A
Revenue
$708,780,000.00
$14,083,000.00
Revenue This Year
$0.08
N/A
Revenue Next Year
$0.98
$783.24
P/E Ratio
$12.20
N/A
Revenue Growth
N/A
128.21
52 Week Low
$3.74
$3.00
52 Week High
$7.33
$5.10

Technical Indicators

Market Signals
Indicator
CRCT
ABUS
Relative Strength Index (RSI) 56.14 48.60
Support Level $4.20 $4.19
Resistance Level $4.26 $4.64
Average True Range (ATR) 0.14 0.19
MACD 0.05 -0.01
Stochastic Oscillator 82.40 44.12

Price Performance

Historical Comparison
CRCT
ABUS

About CRCT Cricut Inc.

Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: